Pfizer Inc (PFE)
26.02
-0.70
(-2.64%)
USD |
NYSE |
Nov 14, 16:00
25.89
-0.12
(-0.48%)
After-Hours: 17:55
Pfizer Revenue (TTM): 59.37B for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 59.37B |
| June 30, 2024 | 55.16B |
| March 31, 2024 | 54.89B |
| December 31, 2023 | 58.50B |
| September 30, 2023 | 69.27B |
| June 30, 2023 | 78.42B |
| March 31, 2023 | 93.16B |
| December 31, 2022 | 100.33B |
| September 30, 2022 | 99.88B |
| June 30, 2022 | 101.28B |
| March 31, 2022 | 92.43B |
| December 31, 2021 | 81.29B |
| September 30, 2021 | 68.88B |
| June 30, 2021 | 55.12B |
| March 31, 2021 | 46.08B |
| December 31, 2020 | 41.65B |
| September 30, 2020 | 32.07B |
| June 30, 2020 | 34.47B |
| March 31, 2020 | 37.87B |
| December 31, 2019 | 40.90B |
| September 30, 2019 | 40.22B |
| June 30, 2019 | 40.84B |
| March 31, 2019 | 41.04B |
| December 31, 2018 | 40.82B |
| September 30, 2018 | 53.37B |
| Date | Value |
|---|---|
| June 30, 2018 | 53.24B |
| March 31, 2018 | 52.67B |
| December 31, 2017 | 52.55B |
| September 30, 2017 | 52.47B |
| June 30, 2017 | 52.35B |
| March 31, 2017 | 52.60B |
| December 31, 2016 | 52.82B |
| September 30, 2016 | 53.24B |
| June 30, 2016 | 52.29B |
| March 31, 2016 | 50.99B |
| December 31, 2015 | 48.85B |
| September 30, 2015 | 47.92B |
| June 30, 2015 | 48.20B |
| March 31, 2015 | 49.12B |
| December 31, 2014 | 49.60B |
| September 30, 2014 | 50.04B |
| June 30, 2014 | 50.33B |
| March 31, 2014 | 50.53B |
| December 31, 2013 | 51.58B |
| September 30, 2013 | 51.92B |
| June 30, 2013 | 52.23B |
| March 31, 2013 | 53.22B |
| December 31, 2012 | 55.70B |
| September 30, 2012 | 53.72B |
| June 30, 2012 | 57.38B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
32.07B
Minimum
Sep 2020
101.28B
Maximum
Jun 2022
65.05B
Average
58.93B
Median
Revenue (TTM) Benchmarks
| Amgen Inc | 32.53B |
| Johnson & Johnson | 87.70B |
| Eli Lilly and Co | 40.86B |
| Merck & Co Inc | 63.17B |
| Moderna Inc | 5.056B |